Earnings Review
Torrent Pharma sees 6-qtr high YoY PAT growth at INR 5.9 bln
This story was originally published at 20:05 IST on 7 November 2025
Register to read our real-time news.Informist, Friday, Nov. 7, 2025
Please click here to read all liners published on this story
--Torrent Pharma Jul-Sept consol net profit INR 5.91 bln
--Analysts saw Torrent Pharma Jul-Sept consol net profit at INR 6 bln
--Torrent Pharma Jul-Sept consol revenue INR 33.02 bln
--Analysts saw Torrent Pharma Jul-Sept consol revenue at INR 32.05 bln
--Torrent Pharma Jul-Sept consol PAT INR 5.91 bln vs INR 4.53 bln year ago
--Torrent Pharma Jul-Sept consol revenue INR 33.02 bln vs INR 28.89 bln
--Torrent Pharma Apr-Sept consol PAT INR 11.39 bln vs INR 9.10 bln year ago
--Torrent Pharma Apr-Sept consol revenue INR 64.80 bln vs INR 57.48 bln
--Torrent Pharma Q2 consol operating EBITDA INR 10.83 bln vs INR 9.39 bln
--Torrent Pharma H1 consol operating EBITDA INR 21.15 bln vs INR 18.43 bln
--Torrent Pharma Jul-Sept consol operating EBITDA margin 32.8%
--Torrent Pharma Q2 consol R&D spend INR 1.56 bln vs INR 1.45 bln year ago
--Torrent Pharma Jul-Sept India revenue INR 18.20 bln, up 12% on year
--Torrent Pharma Q2 India revenue up led by outperformance in focus therapies
--Torrent Pharma Jul-Sept Brazil revenue INR 3.18 bln, up 21% on year
--Torrent Pharma Jul-Sept Germany revenue INR 3.03 bln, up 5% on year
--Torrent Pharma Jul-Sept US business revenue INR 3.37 bln, up 26% on year
By Avishek Rakshit
KOLKATA – Even as Torrent Pharmaceuticals Ltd. reported a healthy on-year revenue and profit growth in the September quarter, which is much more than what it has been reporting for the past several quarters, its performance marginally fell short of the Street's expectation.
The pharmaceuticals company reported a sharp 30.5% on-year increase in its consolidated net profit at INR 5.9 billion during Jul-Sept as against the Street's estimate of INR 6 billion, missing the projection by a thin margin. Incidentally, the net profit growth in the quarter under review is the strongest on-year growth that the company registered in the past six quarters.
Consolidated sales grew by 14.3% on year to a little over INR 33 billion in the September quarter, but fell short of the Street's estimate of INR 32.1 billion. On revenue as well, Torrent Pharma reported an eight-quarter-high revenue growth.
The September quarter also saw the company's expenses growth touch an eight-quarter high as raw material costs and employee benefit expenses climbed up. Wages and other employee benefit expenses, which account for 25% of the company's total expenses, rose 15.5% on year to INR 6.3 billion and raw material costs increased 13.4% on year to INR 3.8 billion, touching peak growth in the past eight quarters.
However, stock-in-trade purchase expenses remained flat at INR 3.8 billion and finance costs declined 25% on year to INR 480 million, which relieved some pressure on the entire expenses. Torrent Pharma's total expenses in the September quarter rose 11.7% on year to INR 24.7 billion.
In the September quarter, the company's consolidated operating earnings before, interest, tax, depreciation, and amortisation grew 15.3% on year to INR 10.8 billion with an EBITDA margin of 32.8%. Its spends on research and development increased 7.6% on year to INR 1.6 billion in the September quarter.
During the first half of the current financial year, Torrent Pharma's consolidated net profit grew 25.2% on year to INR 11.4 billion and consolidated sales increased nearly 13% on year to INR 64.8 billion. The consolidated operating EBITDA during Apr-Sept grew 14.8% on year to INR 21.2 billion.
In India, which accounts for 55% of its top line, revenues grew by 12% on year to INR 18.2 billion owing to its outperformance in focus therapies. Torrent Pharma's chronic business in India grew 13% as against the industry growth of 11% in India. On a moving annual total basis, which is primarily used to compute market share and sales volume growth, Torrent Pharma outperformed the industry growth across focused therapies aided by strong performance of new products, the company said in a statement.
Torrent Pharma has 21 brands in the Top 500 brands in the Indian pharmaceuticals industry with 15 brands having more than INR 1 billion worth of sales.
In the US, which is Torrent Pharma's largest market outside India comprising 10% of its revenue, the top line grew 26% on year to INR 3.4 billion. However, in constant currency revenues of $39 million, the top line growth was 21% on year. The company said that its recent launches in the US achieved their targeted market shares.
In Brazil, the second-most important country for Torrent Pharma outside India, revenues increased 21% on year to INR 3.2 billion, aided by the performance of top brands and recent launches. However, in Brazil, Torrent Pharma has 65 of its products under the review of the Brazilian Health Surveillance Agency - Agncia Nacional de Vigilncia Sanitria.
In Germany, the top line increased by 5% on year to INR 3 billion, but in constant currency terms, the revenue was down by 5% on year to 30 million euros. Torrent Pharma's growth in Germany was impacted due to supply disruption at a third party supplier's end.
Friday, shares of Torrent Pharma closed 0.75% up at INR 3,580 on the National Stock Exchange. The company declared its results after market hours. End
US$1 = INR 88.67
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Edited by Deepshikha Bhardwaj
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
